EGFR and non-small cell lung carcinoma: The results of a prospective, single-arm, Phase II study suggest that the early SBRT of a primary lesion after EGFR-TKI therapy is a potentially safe and effective new approach for treating EGFR-mutant advanced NSCLC [45].